Olivier Rascol

Toulouse, 31000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.

Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.

Journal: Parkinsonism & related disorders

Published: July 18, 2011

Milestones in Parkinson's disease therapeutics.

Milestones in Parkinson's disease therapeutics.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: June 01, 2011

A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease.

A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease.

Journal: Fundamental & clinical pharmacology

Published: May 19, 2011

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Journal: The Lancet. Neurology

Published: April 13, 2011

Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.

Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.

Journal: European journal of neurology

Published: January 25, 2011

Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.

Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: January 12, 2010

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.

Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: December 22, 2009

123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.

123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: October 31, 2009

Rotigotine transdermal delivery for the treatment of Parkinson's disease.

Rotigotine transdermal delivery for the treatment of Parkinson's disease.

Journal: Expert opinion on pharmacotherapy

Published: February 26, 2009

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.

Journal: Neurology

Published: February 18, 2009

Treatments in the early stage of Parkinson disease

Treatments in the early stage of Parkinson disease

Journal: Revue neurologique

Published: August 06, 2008

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.

Journal: Archives of neurology

Published: May 14, 2008

Showing 1-12 of 23

Last Updated: 09/26/2026